Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens
about
The evolution of poxvirus vaccinesDeletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-CDevelopment of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infectionDifferential induction of apoptosis, interferon signaling, and phagocytosis in macrophages infected with a panel of attenuated and nonattenuated poxviruses.Structure of vaccinia virus A46, an inhibitor of TLR4 signaling pathway, shows the conformation of VIPER motif.Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling PathwaysVirological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve ImmunogenicitySafety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses.Enhancing poxvirus vectors vaccine immunogenicity.Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A.Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants.Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.Clinical applications of attenuated MVA poxvirus strain.Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-SpeciIlluminating inflammasome activity in vivo.Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox.Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways.Modulating Vaccinia Virus Immunomodulators to Improve Immunological Memory.The Gene of Goatpox Virus Encodes an Inhibitor of NF-κB and Apoptosis and May Serve as an Improved Insertion Site To Generate Vectored Live Vaccine
P2860
Q26995905-35C3B314-9C82-4938-BD81-53572C8B70E4Q27306437-2CF67284-F6EE-4B06-9E39-34B30276D753Q27321985-9F03D5AD-225A-4298-8AB1-17307BFAA9C4Q33602820-E6052B7D-9FCB-4871-A7E6-29C72EA73DC2Q33870595-C1EB9B2C-04E9-4633-91F7-FB17B75CC941Q34796206-E179D496-7B3B-4B9F-B3ED-23646F6A1ED9Q34991112-24A3DBD6-1B19-4D61-AD21-2DFDA587249CQ35656345-EB96F87C-0C11-4042-A588-A927F2A23572Q36192765-A81DA62C-21A2-4F61-8797-85AA2D0E9460Q36947039-19DAD365-7CF3-4535-8A74-DCCFA7BA681BQ36978452-54D91A22-EC03-4DA2-95A8-5F53E95A71A6Q36980878-C3FFFE8D-C7C0-4EB0-9B17-C49E6943DE73Q37209483-3A565C8F-DABA-4DC3-A06A-E5D6E68A9DC6Q37643731-A858EB97-E34B-43F7-8F9E-D268784658D7Q38156198-EA1AA169-675C-46C4-A8C4-07051B0327A0Q40071705-22D2BE2D-3B0C-45FD-B482-E5B17B8D7B56Q40339467-6A68DCEC-0DDD-45F9-8D55-B70652832766Q40843765-25BA5A85-CF1C-4E91-A3EC-18C50C2B67A9Q45325213-AF4E183E-E2DF-47F2-BFF4-6E3C95A83EA9Q47233214-A319DD52-7B9D-4C06-BB44-F8D1D7F3600AQ47252143-44F0E7B8-EAE8-42DD-8BF8-8E52E7C291C6Q50533334-D34678DB-FAA9-43F9-BDE4-8CF9E69B79DEQ56556724-191D896F-9BBF-42C4-B485-A712D996FB2D
P2860
Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Deletion of the viral anti-apo ...... sponses against HIV-1 antigens
@ast
Deletion of the viral anti-apo ...... sponses against HIV-1 antigens
@en
Deletion of the viral anti-apo ...... sponses against HIV-1 antigens
@nl
type
label
Deletion of the viral anti-apo ...... sponses against HIV-1 antigens
@ast
Deletion of the viral anti-apo ...... sponses against HIV-1 antigens
@en
Deletion of the viral anti-apo ...... sponses against HIV-1 antigens
@nl
prefLabel
Deletion of the viral anti-apo ...... sponses against HIV-1 antigens
@ast
Deletion of the viral anti-apo ...... sponses against HIV-1 antigens
@en
Deletion of the viral anti-apo ...... sponses against HIV-1 antigens
@nl
P2093
P2860
P50
P1433
P1476
Deletion of the viral anti-apo ...... sponses against HIV-1 antigens
@en
P2093
Beatriz Perdiguero
Jose Luis Nájera
Julie Delaloye
Mariano Esteban
Rubén González-Sanz
Victoria Jiménez
P2860
P304
P356
10.1371/JOURNAL.PONE.0048524
P407
P577
2012-10-31T00:00:00Z